Skip to main content
. Author manuscript; available in PMC: 2014 Mar 1.
Published in final edited form as: Clin Pharmacol Ther. 2013 May 9;94(3):394–399. doi: 10.1038/clpt.2013.96

Figure 2. A-D. Effects of CYP2D6 metabolizer phenotype on selected pharmacokinetic parameters.

Figure 2

A Peak dose-normalized plasma metoprolol concentration (Cmax/dose); B Dose-normalized area under the plasma concentration (AUC/dose); C Elimination half-life (t1/2); D Apparent oral clearance (CL/F) The difference between ultra-rapid metabolizers and poor metabolizers in all four parameters is highly statistically significant (all p<0.001). Error bars represent standard deviations.